{
	"oncology": {
		"manual": {
			"chapters": [{
				"title": "DETRESSES VITALES",
				"chapters": [{
					"title": "Urgences et détresses vitales",
					"chapters": [{
						"title": "Prévenir les détresses vitales - La Chaîne de Survie Intra-Hospitalière",
						"htmlPage": "<p>Autant que sa prise en charge curative, <strong>c\u2019est l\u2019identification d\u2019une d\u00E9tresse vitale \u00E0 son d\u00E9but, au stade de dysfonction, qui d\u00E9finit le pronostic<\/strong> du patient. Ainsi :<\/p>\r\n<p><a href=\"foo:\/\/9_1.png\"><img src=\"images\/9_1.png\" class=\"images\"><\/a><\/p>\r\n<address>R\u00E9f\u00E9rences :<br \/>\r\nInspir\u00E9 de P. Michelet, Marseille. Congr\u00E8s SFAR 2013<br \/>\r\nNurmi J, et coll. Acta Anaesthesiol Scand 2005 ; 49 :702-6<br \/>\r\nJones DA, et coll. N Engl J Med 2011 ; 365 :139-46.<br \/>\r\nRapid-Response Teams. Daryl A. Jones, M.D., M.B., B.S., Michael A. DeVita, M.D., and Rnaldo Bellomo,<br \/>\r\nM.D., M.B., B.S.<br \/>\r\nN ENGL J MED 365;2 NEJM.ORG July 14, 2011<\/address>\r\n<address>F. Lion, F. Blot, R\u00E9animation, Gustave Roussy, septembre 2013<\/address>\r\n"
					}, {
						"title": "Critère d'appel du médecin de réanimation - USCM face à une dysfonction viscérale débutante",
						"htmlPage": "<div>\r\n<p>En cas de pathologie justifiant un transfert en r\u00E9animation - USCM, <strong>la pr\u00E9cocit\u00E9 de ce transfert<\/strong>, et plus g\u00E9n\u00E9ralement de la collaboration entre cliniciens d\u2019onco-h\u00E9matologie et de r\u00E9animation, est <strong>un facteur pronostique majeur<\/strong>.<\/p>\r\n<p>L\u2019\u00E9quipe de r\u00E9animation met tout en oeuvre \u00EAtre disponible d\u00E8s que la situation m\u00E9dicale d\u2019un patient pr\u00E9sente des crit\u00E8res de <strong>gravit\u00E9 d\u00E9butante<\/strong> :<\/p>\r\n<p><strong>N\u2019HESITEZ PAS APPELER LE REANIMATEUR !<\/strong><\/p>\r\n<p>Ainsi, face \u00E0 toute <strong>dysfonction<\/strong> (et non d\u00E9faillance) respiratoire, h\u00E9modynamique, r\u00E9nale, m\u00E9tabolique, neurologique, h\u00E9pato-digestive ou infectieuse <strong>d\u00E9butante <\/strong>: (liste non exhaustive)<\/p>\r\n<\/div>\r\n<h1>I. \u00E9valuation coll\u00E9giale de l\u2019\u00E9quipe r\u00E9f\u00E9rente du patient, en vue de d\u00E9finir 3 niveaux d\u2019action :<\/h1>\r\n<ul><li>1. Patient consid\u00E9r\u00E9 \u00AB\u00E0 r\u00E9animer1\u00BB, <\/li>\r\n<li>2. Patient consid\u00E9r\u00E9 \u00AB \u00E0 ne pas transf\u00E9rer en r\u00E9animation - USCM \u00BB, mais discussion souhaitable avec le r\u00E9animateur pour optimiser la prise en charge en salle,<\/li>\r\n<li>3. Patient en phase terminale ou palliative, prise en charge exclusive par l\u2019\u00E9quipe du service d\u2019origine, privil\u00E9giant le confort.<\/li>\r\n<\/ul><h1>II. Si situation 1 ou 2, appel du r\u00E9animateur d\u00E8s que survient: (\u00E9v\u00E9nement d\u2019apparition r\u00E9cente)<\/h1>\r\n<ul><li><strong>Dysfonction respiratoire<\/strong> = 5 litres d\u2019oxyg\u00E8ne min.<\/li>\r\n<li><strong>Dysfonction h\u00E9modynamique<\/strong> = 2 solut\u00E9s de remplissage (collo\u00EFde, cristallo\u00EFde)<\/li>\r\n<li><strong>Dysfonction r\u00E9nale<\/strong> = ur\u00E9e &gt; 12 mmol\/l ou cr\u00E9atinine &gt; 130 \u00B5mol\/l ou multipli\u00E9e par 2.<\/li>\r\n<\/ul><ul><li>Probl\u00E8me infectieux difficile : appel de l\u2019infectiologue, ou, en son absence, du r\u00E9animateur, en cas de choix difficile des anti-infectieux, tableau clinique justifiant d\u2019un pr\u00E9l\u00E8vement particulier (ex. fibro-LBA), etc. ; porte d\u2019entr\u00E9e identifi\u00E9e avec geste de drainage en attente.<\/li>\r\n<li>Toute autre situation impliquant classiquement l\u2019appel du r\u00E9animateur : crise convulsive, coma, arr\u00EAt cardio-respiratoire, etc.<\/li>\r\n<li>Toute autre situation plus inhabituelle, mais dont la complexit\u00E9  justifie une expertise coll\u00E9giale : troubles h\u00E9patiques, digestifs, d\u2019h\u00E9mostase\u2026<\/li>\r\n<li>Dans l\u2019attente d\u2019un transfert vers un autre \u00E9tablissement.<\/li>\r\n<\/ul><h1>III. Apr\u00E8s avis du r\u00E9animateur, le patient est :<\/h1>\r\n<ul><li>Pris en charge en r\u00E9animation pour engagement th\u00E9rapeutique maximal,<\/li>\r\n<li>Pris en charge en unit\u00E9 de soins continus m\u00E9dicaux pour  expertise et traitement, mais avec limitation th\u00E9rapeutique \u00E9ventuelle,<\/li>\r\n<li>Maintenu dans son service d\u2019origine, avec assistance possible du r\u00E9animateur pour la poursuite de la prise en charge, n\u00E9cessairement simplifi\u00E9e.<\/li>\r\n<\/ul><address>1. Patient \u00AB\u00E0 r\u00E9animer\u00BB : cette \u00E9valuation par l\u2019oncologue ou l\u2019h\u00E9matologue est essentielle avant toute prise en charge, qui sera d\u00E9cid\u00E9e coll\u00E9gialement en fonction de crit\u00E8res onco-h\u00E9matologiques d\u2019une part, de crit\u00E8res sp\u00E9cifiques \u00E0 la r\u00E9animation (nature, gravit\u00E9, nombre, r\u00E9versibilit\u00E9 des atteintes visc\u00E9rales) d\u2019autre part.<\/address>\r\n<address> <\/address>\r\n<address>R\u00E9f\u00E9rences : <br \/>\r\nBlot F. Face au probl\u00E8me de la d\u00E9cision d\u2019admission en r\u00E9animation des malades porteurs d\u2019une n\u00E9oplasie. vers une apporche s\u00E9quentielle et concert\u00E9e? Rev Mal Respir 2001; 18 :109-113<\/address>\r\n<address>Azoulay E., Blot F. Crit\u00E8re d\u2019admission  des patients d\u2019oncoh\u00E9matologie en r\u00E9animation. In \u00ABR\u00E9anition en oncoh\u00E9matologie\u00BB, F. Blot et G. Conti, Elsevier, SRLF, Paris 2004, 760-770<\/address>\r\n<address>Raynard B; Comment soign\u00E9s et soignants accueillent-ils les d\u00E9cisions d\u2019admission ou de refus en r\u00E9animation. DEA d\u2019Ethique M\u00E9dicale <\/address>"
					}]
				}, {
					"title": "Critères d'appel du médecin de REA - USCM",
					"htmlPage": "<p>Manuel</p>"
				}, {
					"title": "Arrêt cardiaque",
					"htmlPage": "<p>Manuel</p>"
				}, {
					"title": "Prise en charge initiale du SCA",
					"htmlPage": "<p>Manuel</p>"
				}]
			}, {
				"title": "MEDECINE",
				"chapters": [{
					"title": "Analyses de biologie en garde",
					"htmlPage": "<h4>It works </h4><br>"
				}, {
					"title": "CVC / Principe et complications",
					"chapters": [{
						"title": "Pose de chambre ou de cvc",
						"htmlPage": "<h4>It works </h4><br>"
					}, {
						"title": "Tromboses veineuses sur cvc",
						"htmlPage": "<h4>It works </h4><br>"
					}]
				}]
			}]
		},
		"annexe": {
			"chapters": [{
				"title": "Références",
				"htmlPage": "<p><strong>Comment soigner sans s\u2019user ? Pr\u00E9venir le seps1 ou le syndrome du burn-out<\/strong><\/p>\r\n<p>A. Ramirez AJ, Graham J, Richards MA, et al. (2002) Burnout and psychiatric disorder among cancer clinicians. Br J Cancer 71(6): 1263-9; Whippen DA, Canellos GP (1991) Burnout syndrom in the practice of oncology: results of a random survey of 1000 oncologists. J Clin Oncol 9: 1916-1920.<\/p>\r\n<p>B. Blanchard P, Truchot D, Albiges-Sauvain L, et al. (2010) Prevalence and causes of burnout among oncology residents: a comprehensive nationwide cross-sectional stud. Eur J Cancer 46(15): 2708-2715.<\/p>\r\n<p>C. A ne pas confondre avec l\u2019acceptation psychiatrique du terme caract\u00E9risant l\u2019un des signes cliniques de la schizophr\u00E9nie.<\/p>\r\n<p><strong>Pr\u00E9venir les d\u00E9tresses vitales : la cha\u00EEne de survie intra-hospitali\u00E8re<\/strong><\/p>\r\n<p>Inspir\u00E9 de P. Michelet, Marseille. Congr\u00E8s SFAR 2013<\/p>\r\n<p>Nurmi J, et coll. Acta Anaesthesiol Scand 2005 ; 49 :702-6<\/p>\r\n<p>Jones DA, et coll. N Engl J Med 2011; 365 :139-46.<\/p>\r\n<p>Rapid-Response Teams. Daryl A. Jones, M.D., M.B., B.S., Michael A. DeVita, M.D., and Rnaldo Bellomo, M.D., M.B., B.S.<\/p>\r\n<p>N ENGL J MED 365;2 NEJM.ORG July 14, 2011<\/p>\r\n<p><strong>Crit\u00E8res d\u2019appel du m\u00E9decin de r\u00E9animation-USCM face \u00E0 une dysfonction vis\u00E9rale d\u00E9butante<\/strong><\/p>\r\n<p>Blot F. Face au probl\u00E8me de la d\u00E9cision d\u2019admission en r\u00E9animation des malades porteurs d\u2019une n\u00E9oplasie. Vers une apporche s\u00E9quentielle et concert\u00E9e? Rev Mal Respir 2001; 18 :109-113<\/p>\r\n<p>Azoulay E., Blot F. Crit\u00E8re d\u2019admission  des patients d\u2019oncoh\u00E9matologie en r\u00E9animation. In \u00ABR\u00E9anition en oncoh\u00E9matologie\u00BB, F. Blot et G. Conti, Elsevier, SRLF, Paris 2004, 760-770<\/p>\r\n<p>Raynard B; Comment soign\u00E9s et soignants accueillent-ils les d\u00E9cisions d\u2019admission ou de refus en r\u00E9animation. DEA d\u2019Ethique M\u00E9dicale<\/p>\r\n<p><strong>Prise en charge initiale  du syndrome coronarien aigu  \u00E0 la phase aigu\u00EB<\/strong><\/p>\r\n<p>1. Van de Werf F. et al. Eur Heart J 2008.<\/p>\r\n<p>2. Wijns W. et al. Eur Heart J 2010.<\/p>\r\n<p>3. Hamm C.W. et al. Eur Heart J 2011.<\/p>\r\n<p><strong>Diagnostic des infections li\u00E9es aux CVC<\/strong><\/p>\r\n<p>XII Conf\u00E9rence de Consensus de la SRLF. R\u00E9animation 2003; 12 : 258-265; Siegman-Igra Y et al. J Clin Microbiol 1997;35: 928-936; Cook D et al. Crit Care Med 1997;25: 1417-1424; Raad II et al. Clin Infect Dis 1995; 20: 593-597;  Blot F et al. Lancet 1999;354: 1071-1077.<\/p>\r\n<p><strong>Embolie pulmonaire : traitement<\/strong><\/p>\r\n<p>Kearon C, et coll Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S-94S.<\/p>\r\n<p>Mismetti P, et coll. Recommandations de bonne pratique: pr\u00E9vention et traitement de la maladie thrombo-embolique veineuse en m\u00E9decine. J Mal Vasc. 2010;35:127-36.(disponible sur le site de l\u2019AFSSAPS, maintenant ANSM, <a href=\"http:\/\/www.ansm.sante.fr\/\">www.ansm.sante.fr<\/a><\/p>\r\n<p><strong>Glycopeptides : indications, prescription, surveillance<\/strong><\/p>\r\n<p>Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the IDSA, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49:325-7.<\/p>\r\n<p>Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the IDSA. Clin Infect Dis. 2011, 52 : e56-93.<\/p>\r\n<p>Coll\u00E8ge des Universitaires de Maladies Infectieuses et Tropicales. Glycopeptides et lipopeptides; Oxazolidinones. In : E. Pilly. Maladies Infectieuses et Tropicales. Vivactis Plus Ed 2012 : 64-7.<\/p>\r\n<p>SPILF. 17e conf\u00E9rence de consensus en pathologie infectieuse: Prise en charge des m\u00E9ningites bact\u00E9riennes aigu\u00EBs communautaires. Nov.2008<\/p>\r\n<p><strong>Aminosides : Indications, prescription et surveillance chez l\u2019adulte<\/strong><\/p>\r\n<p>The task force on the prevention, diagnosis and treatment of infective endocarditis of the European Society of Cardiology. Guidelines on the prevention, diagnosis and treatment of infective endocarditis (new version 2009). Eur heart J 2009, 30 : 2369-413.<\/p>\r\n<p>AFSSAPS, SPILF, GPIP. Mise au point sur le bon usage des aminosides administers par voie injectable: gentamicine, tobramycine, n\u00E9tilmicine, amikacine. Mars 2011.<\/p>\r\n<p>Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the IDSA. Clin Infect Dis. 2011, 52 : e56-93.<\/p>\r\n<p>Coll\u00E8ge des Universitaires de Maladies Infectieuses et Tropicales. Aminosides. In : E. Pilly. Maladies Infectieuses et Tropicales. Vivactis Plus Ed 2012 : 47-9.<\/p>\r\n<p>Seemungal BM, Bronstein AM. Aminoglycoside ototoxicity : vestibular function is also vulnerable. BMJ 2007, 35 : 952.<\/p>\r\n<p><a href=\"http:\/\/www.dizziness-and-balance.com\">http:\/\/www.dizziness-and-balance.com<\/a><\/p>\r\n<p>Dang L, Duffull S. Development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis. J Clin Pharmacol 2006; 46(6): 662-73.<\/p>\r\n<p>Teigen MM, Duffull S, Dang L, Johnson DW. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol 2006; 46(11): 1259-67<\/p>\r\n<p><strong>Hypercalc\u00E9mie<\/strong><\/p>\r\n<p>- Flombaum CD. Seminars in Oncology 2000 ;27 :322-334.<\/p>\r\n<p>- Morini\u00E8re P, et coll. In R\u00E9animation m\u00E9dicale. CNERM. Masson, Paris 2001<\/p>\r\n<p><strong>Pr\u00E9vention de la n\u00E9phropathie induite par les produits de contraste iodes (NIPCI)<\/strong><\/p>\r\n<p>Barrett BJ, et al. N Engl J Med 2006 ; 354: 379-86. - Birck R, et al. Lancet, 2003; 362: 598-603. - Merten GJ, et al. JAMA 2004 ; 291: 2328-3<\/p>\r\n<p>- Hoffmann U, et al. J Am Soc Nephrol 2004 ; 15: 407-10. - Tepel M, et al. N Engl J Med 2006; 343: 180-4. - Dussol B, et al. Nephrol Dial Transplant 2006 (Apr 12)<\/p>\r\n<p><strong>Acidoc\u00E9tose diab\u00E9tique (ACD) : prise en charge des 1\u00E8res 24h<\/strong><\/p>\r\n<p>Management of hyperglycemic crises in patients with diabetes. Abbas E. Diabetes care 2001 (24).<\/p>\r\n<p><strong>Pr\u00E9vention et traitement de l\u2019h\u00E9patotoxicit\u00E9 du parac\u00E9tamol<\/strong><\/p>\r\n<p>- Seirafi M, Iten A, Hadengue A. Parac\u00E9tamol : toxicit\u00E9 h\u00E9patique aux doses th\u00E9rapeutiques et populations \u00E0 risque. Revue Med Suisse 2007 : <a href=\"http:\/\/revue.medhyg.ch\/\">http:\/\/revue.medhyg.ch\/<\/a><\/p>\r\n<p>Vitols S. Paracetamol hepatotoxicity at therapeutic doses. J Intern Med 2003; 253: 95-8.<\/p>\r\n<p>Kurtovic J, Riordan SM. Paracetamol-induced hepatotoxicity at recommended dosage. J Intern Med 2003; 253: 240-3.<\/p>\r\n<p>Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006; 296: 87-93. - Durand-Fontanier S, Fourcade L, Abita T, et al. Cons\u00E9quences des h\u00E9patectomies. EMC H\u00E9patologie: 7-038-B-10.<\/p>\r\n<p><strong>Recommandations d\u2019utilisation de l\u2019\u00E9rythropo\u00EF\u00E9tine (EPO)<\/strong><\/p>\r\n<p>EORTC :<\/p>\r\n<p>Bokemeyer C et al. European Organisation for Research and Treatment of Cancer (EORTC). Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007 Jan;43(2):258-70. Review.<\/p>\r\n<p>Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. The Oncologist. 2008 13 Suppl 3:33-6.<\/p>\r\n<p>SOR : Ray-Coquard I et al. Standards, Options et Recommandations (SOR); [Clinical Practice guidelines for the use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin b\u00EAta, darbepoetin) in anaemic patients with cancer: 2007 update (summary report)] Bull Cancer. 2008 Apr 1;95(4):433-41. Review. French.<\/p>\r\n<p>HENKE et al, Do Erytropoietin receptors on cancer cells explain unexpected clinical findings ? ; Journal of clinical Oncology. 2006Oct( 4708-4713).<\/p>\r\n<p>HENKE et al, Erytropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy:randomised,  double-blind, placebo-controlled trial. Lancet 2003Oct(3621255-60).<\/p>\r\n<p>Unpublished in peer-reviewed journals. Publicly available in ODAC briefing on US FDA web site.<\/p>\r\n<p>Bastit L et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008 Apr 1;26(10):1611-8.<\/p>\r\n<p>Pedrazzoli P et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008 Apr 1;26(10):1619-25.<\/p>\r\n<p>RCP :Neorecormon\u00AE (Roche 2011),Eprex\u00AE (JANSSEN-CILAG 2009) et ARANESP\u00AE (AMGEN 2011).<\/p>\r\n<p><strong>Extravasation d\u2019agents anticanc\u00E9reux<\/strong><\/p>\r\n<p>Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus<\/p>\r\n<p>1- Dossier du CNHIM (Centre National Hospitalier d\u2019Information sur le M\u00E9dicament). M\u00E9dicaments utilis\u00E9s en canc\u00E9rologie (4e \u00E9dition). 2001, XXII, 1-2<\/p>\r\n<p>2- Von Heimburg D, Pallua N. Early and late treatment of iatrogenic injection damage. Chirurg 1998; 69: 1378-82<\/p>\r\n<p>3- Blot F, Gledhill J. Traitement des toxicit\u00E9s sp\u00E9cifiques des chimioth\u00E9rapies (surdosages, extravasations, mucites). In R\u00E9animation en oncoh\u00E9matologie, Blot F &amp; Conti G eds. Paris : Elsevier ; 2004. pp 525-38.<\/p>\r\n<p>4- Mouridsen H, et al. Treatment of anthracycline extravasation with Savene (dexrazoxane) : results from two prospective clinical multicentre studies. Ann Oncol 2006 ; Dec 21.<\/p>\r\n<p><strong>Indications et seuils transfusionnels<\/strong><\/p>\r\n<p>1. Transfusions de globules rouges homologues : produits, indications, alternatives. Argumentaire. Les diff\u00E9rents types de concentr\u00E9s de globules rouges. Ao\u00FBt 2002. AFSSAPS, 2002<\/p>\r\n<p>2. Red Blood Cell Transfusion : A Clinical Practice Guideline From the AABB.<\/p>\r\n<p>Ann Intern Med; 26 March 2012<\/p>\r\n<p>3. Gudeline on the Administration of Blood Components. British Committee for Standards in Haematology. December 2012<\/p>\r\n<p>4. Bonnes pratiques de transfusion \u00E0 l\u2019usage des h\u00F4pitaux. Janvier 2010.<\/p>\r\n<p>Conseil sup\u00E9rieur de la Sant\u00E9 (Belgique), 2010<\/p>\r\n<p>5.Transfusion sanguine en r\u00E9animation. Congr\u00E8s national d\u2019anesth\u00E9sie et de r\u00E9animation. 2008<\/p>\r\n<p><strong>Particularit\u00E9s de la prise en charge du patient \u00E2g\u00E9 de plus de 75 ans (ou \u00AB 65 ans poly-pathologique \u00BB)<\/strong><\/p>\r\n<p>Montuclard L et al. Crit Care Med. 2000; 28(10): 3389-95.<\/p>\r\n<p>Garrouste-Orgeas M et al. Intensive Care Med 2006 ; 32 : 1045-51.<\/p>\r\n<p>Thomason JW et al. Crit Care 2005 ;9: R375-81.<\/p>\r\n<p>Vyas H et al. N Engl J Med 2007 ; 357: 2067.<\/p>\r\n<p>Voir aussi : r\u00E9f\u00E9rences HAS sur Intranet-R\u00E9a ; (<a href=\"http:\/\/intranet.igr.fr\/index.php?p_id=934\">http:\/\/intranet.igr.fr\/index.php?p_id=934<\/a>)<\/p>\r\n<p>RMH-Nutrition 2008<\/p>\r\n<p><strong>Pr\u00E9paration avant endoscopie digestive haute pour h\u00E9morragie  (ind\u00E9pendamment du traitement de la cause)<\/strong><\/p>\r\n<p>Frossard Jl, Spahr L, Queneau E, et Al. Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding : a randomized, controlled, double-blind trial. Gastroenterology 2002 ; 123 : 17-23.<\/p>\r\n<p>Coffin B, Pocard M, Panis Y, et al. Erythromycin improves the quality of EGD in patients with acute upper GI bleeding : a randomized controlled study. Gastrointest Endosc 2002 ; 56 : 174-9<\/p>\r\n<p><strong>Pr\u00E9vention et traitement des fistules pancr\u00E9atiques<\/strong><\/p>\r\n<p>Ping Poon RT, et al. Am J Surg 2002; 183: 42-52.<\/p>\r\n<p>Sales JP, et al. Ann Chir 2000 ; 125 : 929-35.<\/p>\r\n<p>Li-Ling J, et al. Br J Surg 2001 ; 88 : 190-9.<\/p>\r\n<p>Martineau H, et al. Am J Surg 1996 ; 172 : 386-95.<\/p>\r\n<p>Fukuchi S, et al. Nutr Clin Pract 1998; 13: 59-65.<\/p>\r\n<p>Bassi C, et al. Surgery 2005 ; 138 : 8-13.<\/p>\r\n<p>Bassi C. et al. Ann Surg 2010 ; 252: 207-14.<\/p>\r\n<p><strong>Examens compl\u00E9mentaires pr\u00E9op\u00E9ratoires en chirurgie programm\u00E9e<\/strong><\/p>\r\n<p>Recommandations formalis\u00E9es d\u2019experts, Examens Compl\u00E9mentaires Pr\u00E9op\u00E9ratoires, SFAR 2011<\/p>\r\n<p>Conf\u00E9rence de consensus, diagnostic de l\u2019insuffisance r\u00E9nale chronique, Soci\u00E9t\u00E9 Fran\u00E7aise de N\u00E9phrologie 2002<\/p>\r\n<p><strong>Pr\u00E9paration pr\u00E9op\u00E9ratoire imm\u00E9diate. Jeune pr\u00E9op\u00E9ratoire et pr\u00E9paration cutan\u00E9e pr\u00E9op\u00E9ratoire<\/strong><\/p>\r\n<p>Mariette C, Alves A, Benoist S, Bretagnol F, Mabrut JY, Slim K. Perioperative care in digestive surgery. Guidelines for the French society of digestive surgery (SFCD). Ann Chir. 2005 Feb;130(2):108-24<\/p>\r\n<p>American Society of Anesthesiologists Committee.  Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Committee on Standards and Practice Parameters. Anesthesiology. 2011 Mar;114(3):495-511.<\/p>\r\n<p><strong>soins postop\u00E9ratoires du patient non compliqu\u00E9<\/strong><\/p>\r\n<p><strong>Gestion d\u2019un traitement anticoagulant pr\u00E9op\u00E9ratoire<\/strong><\/p>\r\n<p>ACPP 2010, HAS 2008, SFAR 2005<\/p>\r\n<p>Chirurgies et actes invasifs chez les patients trait\u00E9s au long cours par un anticoagulant oral anti-IIa ou anti-Xa direct.<\/p>\r\n<p>Propositions du Groupe d\u2019inter\u00EAt en h\u00E9mostase p\u00E9rioperatoire (GIHP) 2011<\/p>\r\n<p><strong>Pr\u00E9paration pr\u00E9op\u00E9ratoire imm\u00E9diate. Rep\u00E9rage de stomie<\/strong><\/p>\r\n<p>\u00AB Le guide des bonnes pratiques en stomath\u00E9rapie chez l\u2019adulte \u2013 ent\u00E9rostomies \u00BB Copyright AFET - 1er trimestre 2003<\/p>\r\n<p><strong>Chirurgie digestive. Pour tous les malades de chirurgie digestive<\/strong><\/p>\r\n<p>Mariette C, Alves A, Benoist S, Bretagnol F, Mabrut JY, Slim K. Perioperative care in digestive surgery. Guidelines for the French society of digestive surgery (SFCD). Ann Chir. 2005 Feb;130(2):108-24<\/p>\r\n<p>Zaouter C, Wuethrich P, Miccoli M, Carli F. Early removal of urinary catheter leads to greater post-void residuals in patients with thoracic epidural. Acta Anaesthesiol Scand. 2012 Sep;56(8):1020-5.<\/p>\r\n<p><strong>Chirurgie digestive SPO \u0152sophagectomie<\/strong><\/p>\r\n<p>Mariette C, Alves A, Benoist S, Bretagnol F, Mabrut JY, Slim K. Perioperative care in digestive surgery. Guidelines for the French society of digestive surgery (SFCD). Ann Chir. 2005 Feb;130(2):108-24<\/p>\r\n<p>Johansson J, Oberg S, Wenner J, Zilling T, Johnsson F, von Holstein CS, Walther B. Impact of proton pump inhibitors on benign anastomotic stricture formations after esophagectomy and gastric tube reconstruction: results from a randomized clinical trial. Ann Surg. 2009 Nov;250(5):667-73.<\/p>\r\n<p>Mariette C, Triboulet JP. Complications following oesophagectomy: mechanism, detection, treatment and prevention. J Chir (Paris). 2005 Nov-Dec;142(6):348-54.<\/p>\r\n<p><strong>Chirurgie digestive. SPO Gastrectomie totale<\/strong><\/p>\r\n<p>Mariette C, Alves A, Benoist S, Bretagnol F, Mabrut JY, Slim K. Perioperative care in digestive surgery. Guidelines for the French society of digestive surgery (SFCD). Ann Chir. 2005 Feb;130(2):108-24<\/p>\r\n<p><strong>Chirurgie digestive. SPO Gastrectomie partielle<\/strong><\/p>\r\n<p>Mariette C, Alves A, Benoist S, Bretagnol F, Mabrut JY, Slim K. Perioperative care in digestive surgery. Guidelines for the French society of digestive surgery (SFCD). Ann Chir. 2005 Feb;130(2):108-24<\/p>\r\n<p>Jo DH, Jeong O, Sun JW, Jeong MR, Ryu SY, Park YK. Feasibility study of early oral intake after gastrectomy for gastric carcinoma. J Gastric Cancer. 2011 Jun;11(2):101-8.<\/p>\r\n<p>Yamada T, Hayashi T, Cho H, Yoshikawa T, Taniguchi H, Fukushima R, Tsuburaya A. Usefulness of enhanced recovery after surgery protocol as compared with conventional perioperative care in gastric surgery.<\/p>\r\n<p>Gastric Cancer. Jan 2012 ;15(1):34-41.<\/p>\r\n<p><strong>Chirurgie digestive. SPO H\u00E9patectomies<\/strong><\/p>\r\n<p>Mariette C, Alves A, Benoist S, Bretagnol F, Mabrut JY, Slim K. Perioperative care in digestive surgery. Guidelines for the French society of digestive surgery (SFCD). Ann Chir. 2005 Feb;130(2):108-24<\/p>\r\n<p><strong>Chirurgie digestive. SPO Duod\u00E9no-pancr\u00E9atectomie c\u00E9phalique<\/strong><\/p>\r\n<p>Mariette C, Alves A, Benoist S, Bretagnol F, Mabrut JY, Slim K. Perioperative care in digestive surgery. Guidelines for the French society of digestive surgery (SFCD). Ann Chir. 2005 Feb;130(2):108-24<\/p>\r\n<p>Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, Neoptolemos J, Sarr M, Traverso W, Buchler M; International Study Group on Pancreatic Fistula Definition. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005 Jul;138(1):8-13.<\/p>\r\n<p><strong>Chirurgie digestive. SPO Pancr\u00E9atectomie caudale<\/strong><\/p>\r\n<p>Mariette C, Alves A, Benoist S, Bretagnol F, Mabrut JY, Slim K. Perioperative care in digestive surgery. Guidelines for the French society of digestive surgery (SFCD). Ann Chir. 2005 Feb;130(2):108-24<\/p>\r\n<p>Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, Neoptolemos J, Sarr M, Traverso W, Buchler M; International Study Group on Pancreatic Fistula Definition. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005 Jul;138(1):8-13.<\/p>\r\n<p><strong>Chirurgie digestive. SPO Colectomie par laparotomie<\/strong><\/p>\r\n<p>Mariette C, Alves A, Benoist S, Bretagnol F, Mabrut JY, Slim K. Perioperative care in digestive surgery. Guidelines for the French society of digestive surgery (SFCD). Ann Chir. 2005 Feb;130(2):108-24<\/p>\r\n<p>Gustafsson UO, Scott MJ, Schwenk W, Demartines N, Roulin D, Francis N, McNaught CE, Macfie J, Liberman AS, Soop M, Hill A, Kennedy RH, Lobo DN, Fearon K, Ljungqvist O. Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS(\u00AE)) Society recommendations.Clin Nutr. 2012 Dec;31(6):783-800.<\/p>\r\n<p><strong>Chirurgie digestive. SPO Proctectomie<\/strong><\/p>\r\n<p>Mariette C, Alves A, Benoist S, Bretagnol F, Mabrut JY, Slim K. Perioperative care in digestive surgery. Guidelines for the French society of digestive surgery (SFCD). Ann Chir. 2005 Feb;130(2):108-24<\/p>\r\n<p>Nygren J, Thacker J, Carli F, Fearon KC, Norderval S, Lobo DN, Ljungqvist O, Soop M, Ramirez J. Guidelines for perioperative care in elective rectal\/pelvic surgery: Enhanced Recovery After Surgery (ERAS(\u00AE)) Society recommendations. Clin Nutr. 2012 Dec;31(6):801-16.<\/p>\r\n<p><strong>Chirurgie digestive. SPO par laparoscopie<\/strong><\/p>\r\n<p>Gustafsson UO, Scott MJ, Schwenk W, Demartines N, Roulin D, Francis N, McNaught CE, Macfie J, Liberman AS, Soop M, Hill A, Kennedy RH, Lobo DN, Fearon K, Ljungqvist O. Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS(\u00AE)) Society recommendations.Clin Nutr. 2012 Dec;31(6):783-800.<\/p>\r\n<p>Nygren J, Thacker J, Carli F, Fearon KC, Norderval S, Lobo DN, Ljungqvist O, Soop M, Ramirez J. Guidelines for perioperative care in elective rectal\/pelvic surgery: Enhanced Recovery After Surgery (ERAS(\u00AE)) Society recommendations. Clin Nutr. 2012 Dec;31(6):801-16.<\/p>\r\n<p><strong>Perfusions isol\u00E9es de pelvis. SPO perfusions isol\u00E9es de pelvis<\/strong><\/p>\r\n<p>Essai de phase III comparant comparant la perfusion isol\u00E9e pelvienne (PIP) avec du TNF0,3 mg et du melphalan 1,5 mg\/kg versus traitement standard dans les tumeurs pelviennes localement \u00E9volu\u00E9es d\u2019origine gyn\u00E9cologique ou digestive, Investigateur principal Dr Jane Muret<\/p>\r\n<p><strong>Soins postop\u00E9ratoires du patient non compliqu\u00E9. Prise en charge d\u2019une jejunostomie d\u2019alimentation<\/strong><\/p>\r\n<p>Gabor et al. Early enteral feeding compared with parenteral nutrition after oesophageal or oesophagogastric resection and reconstruction. (2005), 93,509-513<\/p>\r\n<p>Couper et al. (2011) Proceedings of the Nutrition Society<\/p>\r\n<p>Markides et al. Nutritional access routes following oesophagectomy- a systematic review. Eur J of Clin Nut (2011) 65, 565-573<\/p>\r\n<p>Aiko et al. Beneficial Effects of Immediate Enteral Nutrition After Esophageal Cancer Surgery. Surg Today (2001) 31:971-978.<\/p>\r\n<p>Barlow et al. Prospective multicentre randomised controlled trial of early enteral nutrition for patients undergoing major upper GI surgical resection. Clinical Nutrition (2011) 30: 560-566.<\/p>\r\n<p>Diaz de Liano et al. Cir Esp. 2005; 77 (5):263-266.<\/p>\r\n<p>Gupta et al 2009 Benefits versus risks: A prospective audit. Feeding jejunostomy during esophagectomy. World J Surg 33, 1432-1438<\/p>\r\n<p>Wakefield et al. 1995 Use of a feeding jejunostomy after oesophagogastric surgery. Br J Surg 82, 811-813<\/p>\r\n<p>Sarr MG. Appropriate use, complications and advantages demonstrated in 500 consecutive needle catheter jejunostomies.Br J Surg. 1999 Apr;86(4):557-61.<\/p>\r\n<p><strong>Soins postop\u00E9ratoires du patient non compliqu\u00E9. Prise en charge p\u00E9riop\u00E9ratoire  du patient diab\u00E9tique<\/strong><\/p>\r\n<p>Gestion p\u00E9riop\u00E9ratoire du diab\u00E8te SFAR 2008<\/p>\r\n<p>Protocole Gustave Roussy<\/p>\r\n<p><strong>Soins postop\u00E9ratoires du patient non compliqu\u00E9. Drain de Levy (H\u00E9liosonde\u00AE)<\/strong><\/p>\r\n<p>Degremont R, Brehant O, Fuks D, Sabbagh C, Dhahri A, Browet F, Mahjoub Y, Regimbeau JM. Management of supra-mesocolic peritonitis using the Levy helicoid drain (H\u00E9lisonde\u00AE). J Visc Surg. 2011 Sep;148(4) 291-8<\/p>\r\n<p><strong>Soins postop\u00E9ratoires du patient non compliqu\u00E9. R\u00E8gles de transfusion p\u00E9riop\u00E9ratoire<\/strong><\/p>\r\n<p>Gestion d\u2019une thrombop\u00E9nie en anesth\u00E9sie, conf\u00E9rence d\u2019actualisation, SFAR 2006<\/p>\r\n<p>Seuil transfusionnel en anesth\u00E9sie r\u00E9animation, Soci\u00E9t\u00E9 fran\u00E7aise de vigilance et de th\u00E9rapeutique transfusionnelle, 2006<\/p>\r\n<p>Transfusion de plaquettes, AFFSAPS 2003<\/p>\r\n<p>Protocole Gustave Roussy<\/p>\r\n<p><strong>Soins postop\u00E9ratoires du patient non compliqu\u00E9. Naus\u00E9es et vomissements<\/strong><\/p>\r\n<p><strong> postop\u00E9ratoires (NVPO) chez l\u2019adulte<\/strong><\/p>\r\n<p>Conf\u00E9rence d\u2019experts SFAR 2007<\/p>\r\n<p>Gan et al. Consensus guidelines for managing postoperative N and V. Anesth Analg, 2003. 97(1): p. 62-71.<\/p>\r\n<p> Habib et al. Evidence-based management of postoperative V and V: a review. Can J Anaesth, 2004. 51(4): 326-41.<\/p>\r\n<p>Odin et al., Postoperative nausea and vomiting: cost and therapeutic algorithm. Part II: high-risk patients and late PONV. Ann Fr Anesth Reanim, 2004. 23(6): 581-8.<\/p>\r\n<p><strong>Chylop\u00E9ritoine et chylothorax<\/strong><\/p>\r\n<p>Chalret du Rieu M, et al. J Chir Visc 2011 ; 148 : 392-9.<\/p>\r\n<p><strong>Prise en charge de la d\u00E9pendance alcoolique<\/strong><\/p>\r\n<p>Tonnesen H, Rosenberg J, Nielsen HJ, et al. Effects of preoperative abstinence on poor postoperative outcome in alcohol misusers : randomised controlled trial. BMJ 1999; 318: 1311-6.  - Spies CD, Rommelspacher H. Alcohol withdrawal in the surgical patient: prevention and treatment. Anest Analg 1999; 88: 946-54.  - Objectifs, indications et modalit\u00E9s de sevrage du patient alcoolo d\u00E9pendant, textes de recommandations SFA 1999 : <a href=\"http:\/\/www.anaes.fr\">www.anaes.fr<\/a><\/p>\r\n<p>Gold AJ Rimal A, Nolan A et al. A strategy of escalating doses of benzodiazepines and Phenobarbital administration reduces the need for mechanical ventilation in delirium tremens. Crit Care Med 2007 March; 35(3):724-730<\/p>\r\n<p><strong>Traitement symptomatique de l\u2019occlusion intestinale sur carcinose p\u00E9riton\u00E9ale<\/strong><\/p>\r\n<p>Traitement symptomatique de l\u2019occlusion intestinale sur carcinose p\u00E9riton\u00E9ale : Recommandations de bonnes pratiques cliniques.<\/p>\r\n<p>Groupe de travail pluri-professionnel et membres de diff\u00E9rentes soci\u00E9t\u00E9s savantes, septembre 2012<\/p>\r\n<p>M\u00E9decine palliative (2012) 11, S5-S24<\/p>\r\n"
			}, {
				"title": "Mentions légales",
				"htmlPage": "<p>Ce manuel propose un certain nombre d\u2019indications et propositions diagnostiques et th\u00E9rapeutiques dans le cadre de l\u2019exercice m\u00E9dical \u00E0 Gustave Roussy. En tout \u00E9tat de cause, le m\u00E9decin prescripteur est et demeure enti\u00E8rement responsable de sa prescription. Les auteurs du manuel ne pourront \u00EAtre tenus pour responsables de tout incident ou accident, aux personnes ou aux biens, qui pourrait r\u00E9sulter de l\u2019utilisation de produits, m\u00E9thodes, instructions ou id\u00E9es d\u00E9crits dans ce manuel. En raison de l\u2019\u00E9volution rapide de la science m\u00E9dicale, les auteurs recommandent qu\u2019une v\u00E9rification intervienne syst\u00E9matiquement pour les diagnostics et les posologies.<\/p>\r\n<p>Les num\u00E9ros de t\u00E9l\u00E9phones et bip indiqu\u00E9s dans ce manuel sont \u00E0 l\u2019usage des personnels de Gustave Roussy.<\/p>\r\n<p>Manuel pratique d\u2019oncologie de Gustave Roussy \u00E0 l\u2019usage des internes m\u00E9decine, chirurgie, anesth\u00E9sie, r\u00E9animation, soins de support \u00A9Gustave Roussy Cancer Campus Grand Paris - septembre 2013<\/p>\r\n<p>Il est interdit de reproduire, m\u00EAme partiellement, le pr\u00E9sent manuel sans l\u2019autorisation expresse des auteurs<\/p>"
			}, {
				"title": "Contributeurs",
				"htmlPage": "<p>Sous la direction de :<\/p>\r\n<ul><li>Dr Benjamin BESSE<\/li>\r\n<li>Dr Fran\u00E7ois BLOT<\/li>\r\n<li>Dr Lauriane BORDENAVE<\/li>\r\n<li>Dr Sarah DAUCHY<\/li>\r\n<li>Dr Charles HONORE<\/li>\r\n<\/ul><p>R\u00E9dacteurs :<\/p>\r\n<ul><li>K. Alexandrova<\/li>\r\n<li>L. Benajiba<\/li>\r\n<li>E. Bentivegna<\/li>\r\n<li>V. Billard<\/li>\r\n<li>F. Blot<\/li>\r\n<li>S. Bonvalot<\/li>\r\n<li>L. Bordenave<\/li>\r\n<li>G. Bouroche<\/li>\r\n<li>A. Cavalcanti<\/li>\r\n<li>L. Chalumeau-Lemoine<\/li>\r\n<li>P. Collet<\/li>\r\n<li>T. De Baere<\/li>\r\n<li>F. Deschamps<\/li>\r\n<li>L. Douard-Troalen<\/li>\r\n<li>F. Dumont<\/li>\r\n<li>D. Elias<\/li>\r\n<li>G. Farouil<\/li>\r\n<li>B. Gachot<\/li>\r\n<li>P. Girard<\/li>\r\n<li>D. Go\u00E9r\u00E9<\/li>\r\n<li>P. Gorphe<\/li>\r\n<li>S. Gouy<\/li>\r\n<li>D. Hartl<\/li>\r\n<li>C. Honor\u00E9<\/li>\r\n<li>F. Kolb<\/li>\r\n<li>N. Landry Dattee<\/li>\r\n<li>V. Lapierre<\/li>\r\n<li>S. Laurent<\/li>\r\n<li>S. Leboulleux<\/li>\r\n<li>F. Lion<\/li>\r\n<li>C. Lopez<\/li>\r\n<li>G. Mamelle<\/li>\r\n<li>A. Marty<\/li>\r\n<li>C. Mendes<\/li>\r\n<li>H. Mirghani<\/li>\r\n<li>P. Morice<\/li>\r\n<li>A. Moya-Plana<\/li>\r\n<li>J. Muret<\/li>\r\n<li>S. Proust<\/li>\r\n<li>B. Raynard<\/li>\r\n<li>F. Rimareix<\/li>\r\n<li>P. Roubay<\/li>\r\n<li>B. Sarfati<\/li>\r\n<li>N. Sellami<\/li>\r\n<li>A. Stoclin<\/li>\r\n<li>S. Suria<\/li>\r\n<li>S. Temam<\/li>\r\n<li>E. Treillet<\/li>\r\n<li>C. Uzan<\/li>\r\n<li>S. Voisin-Saltiel<\/li>\r\n<\/ul><p>Et la participation de :<\/p>\r\n<ul><li>L. Robert-Thomas<\/li>\r\n<li>P. Collet<\/li>\r\n<\/ul>"
			}]
		}
	}
}
